Preview

Current Pediatrics

Advanced search

Homocystinuria: Literature Review and Clinical Case Description

https://doi.org/10.15690/vsp.v18i3.2036

Abstract

Homocystinuria is rare autosomal-recessive monogenic disorder associated with disturbance of methionine metabolism due to liver enzyme cystathionine--synthetase (CBS) deficit. That in turn causes elevated concentration of homocystein and its metabolites in blood and urine. The main clinical manifestations of homocystinuria are: myopia, ectopia lentis, psychomotor retardation, learning difficulties, mental retardation, mental illnesses, behaviour problems, paroxysms, extrapyramidal symptoms, skeletal anomalies (body height), long limbs — dolichostenomelia and arachnodactylia (Marfan Phenotype), pectus carinatum, valgus lower limbs, scoliosis, osteoporosis, thromboembolic disorders. Diagnostics of homocystinuria is based on clinical findings and laboratory changes (increase of methionine and homocysteine levels in serum). There is prenatal and DNA-diagnostics (genetic variants in CBS gene). Revealing of homocystinuria demands examination of first-degree relatives. Therapy of patients with homocystinuria includes not only diet therapy but also pyridoxine, folic acid, betaine administration. Syndromic concomitant therapy is also used. The description of the patient with severe B6-resistant form of homocystinuria is given in this article.

About the Authors

Natalia V. Buchinskaya
Saint Petersburg State Pediatric Medical University; Diagnostic (Medical Genetic) Center, Saint Petersburg
Russian Federation

Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests


Eugenia A. Isupova
Saint Petersburg State Pediatric Medical University
Russian Federation

Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests


Mikhail M. Kostik
Saint Petersburg State Pediatric Medical University; Almazov National Medical Research Centre
Russian Federation

Disclosure of interest: receiving fees for giving lectures on behalf of Pfizer, AbbVie, Novartis, Sanofi companies


References

1. OMIM. Homocystinuria due to cystathionine beta-synthase deficiency [cited 2016 March 8]. Available from: https://www.omim.org/ entry/236200.

2. Fatima S, Hafeez A, Lijaz A, et al. Classical homocystinuria in a juvenile patient. J Coll Physicians Surg Pak. 2018;28(6):488–489. doi: 10.29271/jcpsp.2018.06.488.

3. Kadurina TI. Hereditary collagen disorders. Clinical features, diagnosis, treatment, follow-up. St. Petersburg: Nevskij Dialekt; 2000. 271 р. (In Russ).

4. Gomotsistinuriya u detej. Klinicheskie rekomendatsii [Internet]. Moscow: Soyuz pediatrov Rossii; 2016. (In Russ). Доступно по: https://medi. ru/klinicheskie-rekomendatsii/gomotsistinuriya-u-detej_13984/. Ссылка активна на 12.04.2019.

5. Poloni S, Sperb-Ludwig F, Borsatto T, et al. CBS mutations are good predictors for B6-responsiveness: a study based on the analysis of 35 Brazilian Classical Homocystinuria patients. Mol Genet Genomic Med. 2018;6(2):160–170. doi: 10.1002/ mgg3.342.

6. Morris AA, Kozich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40(1):49–74. doi: 10.1007/s10545-016-9979-0.

7. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metab. 2010;99(1):1–3. doi: 10.1016/j.ymgme.2009.09.009.

8. Urreizti R, Asteggiano C, Bermudez M, et al. The p.T191M mutation of the CBS gene is highly prevalent among homocystinuric patients from Spain, Portugal and South America. J Hum Genet. 2006;51(4):305–313. doi: 10.1007/s10038-006-0362-0.

9. Semyachkina AN, Voskoboeva EYu, Voinova VYu, et al. The clinical and genetic aspects and pathogenic mechanisms of classical homocystinuria in children. Rossiiskii vestnik perinatologii i pediatrii. 2013;58(3):30–37. (In Russ).

10. Yap S, Naughten E. Homocystinuria due to cystathionine betasynthase deficiency in Ireland: 25 years’ experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21(7):738–747.

11. Mudd, SH, Levy, HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds.). The metabolic and molecular bases of inherited disease. Vol. I. 7th ed. New York: McGraw-Hill; 1995. рp. 1279–1327.

12. Moorthie S, Cameron L, Sagoo GS, et al. Systematic rewiew and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases. J Inherit Metab Dis. 2014;37(6):889–898. doi: 10.1007/s10545-014-9729-0.

13. Zschocke J, Kebbewar M, Gan-Schreier H, et al. Molecular neonatal screening for homocystinuria in the Qatari population. Hum Mutat. 2009;30(6):1021–1022. doi: 10.1002/humu.20994.

14. Schienle HW, Seitz R, Nawroth P, et al. Thrombomodulin and ristocetinfactor in homocystinuria: a study in two siblings. Thomb Res. 1995;77(1):79–86. doi: 10.1016/0049-3848(95)90867-f.

15. Ismayilova N, MacKinnon AD, Mundy H, Fallon P. Reversible cerebral white matter abnormalities in homocystinuria. JIMD Rep. 2019;44:115–119. doi: 10.1007/8904_2018_135.

16. Mudd SH, Scovby F, Levy HL, et al. The natural history of homocystinuria due to cystationine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1–31.

17. Gus PI, Pilati NP, Schoenardie BO, Marinho DR. Classic homocystinuria and ceratoconus: a case report. Arq Bras Oftalmol. 2018; 81(4):336–338. doi: 10.5935/0004-2749.20180065.

18. Gowda VK, Nanjundappa RC, Pendharkar H, Benakappa N. Homocystinuria with cerebral venous sinus thrombosis: excellent recovery with intravenous recombinant tissue plasminogen activator. Iran J Child Neurol. 2017;11(3):48–52. doi: 10.22037/ijcn. v11i3.10528.

19. Stabler SP, Korson M, Jethva R, et al. Metabolic profiling of total homocysteine and related compounds in hyperhomocysteinemia: utility and limitations in diagnosing the cause of puzzling thrombophilia in a family. JIMD Rep. 2013;11:149–163. doi: 10.1007/8904_2013_235.

20. Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2001;24(4):437–447. doi: 10.1023/a:1010525528842.

21. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu anemii, obuslovlennoj defitsitom V12 [Internet]. Moscow; 2015. (In Russ). Доступно по: http://nodgo.org/sites/default/ files/02.%20%20%D0%90%D0%BD%D0%B5%D0%BC%D0%B8%D 0%B8%20%D0%92%2012.pdf. Ссылка активна на 12.04.2019.

22. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu folievodefitsitnykh anemij [Internet]. Moscow; 2015. (In Russ).] Доступно по: http://nodgo.org/sites/default/files/ 25%20%28%D0%93%29%D0%A4%D0%BE%D0%BB%D0%B8 %D0%B5%D0%B2%D0%BE%D0%B4%D0%B5%D1%84%D0% B8%D1%86%D0%B8%D1%82%D0%BD%D0%B0%D1%8F%20 %D0%B0%D0%BD%D0%B5%D0%BC%D0%B8%D1%8F.pdf. Ссылка активна на 12.04.2019.

23. BIMDG. Homocystinuria. HCU clinical management guidelines [cited 17 Jan 2017]. Available from: http://www.bimdg.org.uk/site/ guidelines-enbs.asp?t=3.

24. Homocystinuria (HCU) dietetic management pathway. Vol. 1 [cited 2 April 2015]. Available from: http://www.bimdg.org.uk/ store/enbs//HCU_Dietetic_Management_Pathway_V1_ April_2015_215380_12052015.pdf.

25. Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet. 2002;108(1):57–63. doi: 10.1002/ajmg.10186.

26. Kraus JP, Janosik M, Kozich V, et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 1999;13(5):362–375. doi: 10.1002/(sici)1098-1004(1999)13:53.3.co;2-b.


Review

For citations:


Buchinskaya N.V., Isupova E.A., Kostik M.M. Homocystinuria: Literature Review and Clinical Case Description. Current Pediatrics. 2019;18(3):187-195. (In Russ.) https://doi.org/10.15690/vsp.v18i3.2036

Views: 15176


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)